Drug intelligence / Profile preview

PtC5Mn

Development stage: Preclinical
Lead developer: Synchrotron SOLEIL
Modality: Small Molecules
Administration: Not Stated

Overview

PtC5Mn is a **metal-based anticancer agent** designed as a manganese (II)-containing prodrug with significant antiproliferative activity observed in preclinical cancer models. It demonstrates enhanced antitumor effects compared to oxaliplatin and affects tumor spheroid proliferation, indicating a distinct mechanism of action. The drug's development is targeted toward neoplasms, especially within the digestive system, and its chemical design suggests coordinated cytotoxicity leveraging both platinum and manganese[3][4]. The developer is Synchrotron Soleil SC, and the highest reported research and development status is preclinical[1][2][3][4].

Brand names: PtC5MnPtC-5MnPtC 5Mn
Other names: PtC5MnPtC-5MnPtC 5Mn

Targets

DNA

Beyond the preview

Go deeper on PtC5Mn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PtC5Mn.

Explore the full profile